Mirum Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov 25, 2019--
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the Evercore ISI 2 nd Annual HealthCONx Conference.
A live audio webcast and archive of the presentation will be available at http://ir.mirumpharma.com
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). For more information, visit MirumPharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191125005078/en/
CONTACT: Media Contact:
Heidi Chokeir, Ph.D.
firstname.lastname@example.org Investor Contact:
Ian Clements, Ph.D.
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: Mirum Pharmaceuticals, Inc.
Copyright Business Wire 2019.
PUB: 11/25/2019 08:30 AM/DISC: 11/25/2019 08:30 AM